Loading...
•
Dec 31, 2022
TransMedics Q4 2022 Earnings Report
TransMedics experienced substantial revenue growth driven by the expansion of the NOP program.
Key Takeaways
TransMedics reported a significant increase in revenue for Q4 2022, driven by the expansion of their National OCS Program (NOP). Total revenue reached $31.4 million, a 225% increase compared to Q4 2021. The company's net loss decreased to $6.7 million from $12.7 million in the same quarter of the previous year.
Total revenue increased by 225% to $31.4 million compared to Q4 2021.
Gross margin was 66% compared to 72% in Q4 2021.
Net loss decreased to $6.7 million compared to $12.7 million in Q4 2021.
Full year revenue increased by 209% to $93.5 million compared to 2021.
Forward Guidance
TransMedics expects total revenue for full-year 2023 to be in the range of $138 million to $145 million, which represents 48% to 55% growth compared to the company’s prior year revenue.
Positive Outlook
- Total revenue for full-year 2023 expected to be in the range of $138 million to $145 million.
- Revenue growth of 48% to 55% compared to the company’s prior year revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...